Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32305093

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2020 Apr 18
First author
Sharman JP

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Apr 18;395(10232):1234-1236. doi: 10.1016/S0140-6736(20)30372-X.
    note
    Source null
    related pmid
    32305083
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Jul;17(7):390. doi: 10.1038/s41571-020-0381-3.
    note
    Source null
    related pmid
    32358576
    relationship
    Comment in
  3. citation
    Lancet. 2020 May 30;395(10238):1694. doi: 10.1016/S0140-6736(20)31018-7.
    note
    Source null
    related pmid
    32473678
    relationship
    Erratum in

Authors and identifiers

  1. name
    Sharman JP
    type
    Author
  2. name
    Egyed M
    type
    Author
  3. name
    Jurczak W
    type
    Author
  4. name
    Skarbnik A
    type
    Author
  5. name
    Pagel JM
    type
    Author
  6. name
    Flinn IW
    type
    Author
  7. name
    Kamdar M
    type
    Author
  8. name
    Munir T
    type
    Author
  9. name
    Walewska R
    type
    Author
  10. name
    Corbett G
    type
    Author
  11. name
    Fogliatto LM
    type
    Author
  12. name
    Herishanu Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sharman JP
    type
    Author
  2. name
    Egyed M
    type
    Author
  3. name
    Jurczak W
    type
    Author
  4. name
    Skarbnik A
    type
    Author
  5. name
    Pagel JM
    type
    Author
  6. name
    Flinn IW
    type
    Author
  7. name
    Kamdar M
    type
    Author
  8. name
    Munir T
    type
    Author
  9. name
    Walewska R
    type
    Author
  10. name
    Corbett G
    type
    Author
  11. name
    Fogliatto LM
    type
    Author
  12. name
    Herishanu Y
    type
    Author
bibliography ids
  1. nci-bib-d100d8b7e39d6432885c7e58
book metadata
content sha256
c53ce6c722824598f4b927837a43ee4766ae8cb913199fdd4bb3696059171a00
document type
citation
dois
  1. 10.1016/S0140-6736(20)30262-2
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:32305093
immutable id
pubmed:32305093@c53ce6c722824598f4b927837a43ee4766ae8cb913199fdd4bb3696059171a00
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10232
name
Lancet (London, England)
nlm unique id
2985213R
pages
1278-1291
volume
395
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Apr 18;395(10232):1234-1236. doi: 10.1016/S0140-6736(20)30372-X.
    note
    Source null
    related pmid
    32305083
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Jul;17(7):390. doi: 10.1038/s41571-020-0381-3.
    note
    Source null
    related pmid
    32358576
    relationship
    Comment in
  3. citation
    Lancet. 2020 May 30;395(10238):1694. doi: 10.1016/S0140-6736(20)31018-7.
    note
    Source null
    related pmid
    32473678
    relationship
    Erratum in
outcomes validated
false
pmid
32305093
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
66007f2ffab90f11d2776ecbebaed9245d41bc1ec71e0ab825245aee0af8e26a
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Apr 18
precision
day
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32305093/
title
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

Preserved source evidence · Not medical advice